Advanced

Haematopoetic stem cell transplantation for refractory autoimmune cytopenia

Passweg, JR; Rabusin, M; Musso, M; Beguin, Y; Cesaro, S; Ehninger, G; Espigado, I; Iriondo, A; Jost, L and Koza, V, et al. (2004) In British Journal of Haematology 125(6). p.749-755
Abstract
This study describes the outcome of patients receiving haematopoietic stem cell transplantation (HSCT) to treat severe refractory autoimmune cytopenia. The registry of the European Group of Blood and Marrow Transplantation holds data on 36 patients receiving 38 transplants, the first transplant was autologous for 27 and allogeneic for nine patients. Patients had autoimmune haemolytic anaemia (autologous: 5; allogeneic: 2), Evans's syndrome (autologous: 2; allogeneic: 5); immune thrombocytopenia (autologous: 12), pure red cell aplasia (autologous: 4; allogeneic: 1), pure white cell aplasia (autologous: 1; allogeneic 1), or thrombotic thrombocytopenic purpura (autologous: 3). Patients had longstanding disease having failed multiple prior... (More)
This study describes the outcome of patients receiving haematopoietic stem cell transplantation (HSCT) to treat severe refractory autoimmune cytopenia. The registry of the European Group of Blood and Marrow Transplantation holds data on 36 patients receiving 38 transplants, the first transplant was autologous for 27 and allogeneic for nine patients. Patients had autoimmune haemolytic anaemia (autologous: 5; allogeneic: 2), Evans's syndrome (autologous: 2; allogeneic: 5); immune thrombocytopenia (autologous: 12), pure red cell aplasia (autologous: 4; allogeneic: 1), pure white cell aplasia (autologous: 1; allogeneic 1), or thrombotic thrombocytopenic purpura (autologous: 3). Patients had longstanding disease having failed multiple prior treatments. Among 26 evaluable patients mobilized for autologous HSCT, three died of treatment-related causes, one died of disease progression, seven were non-responders, six patients had transient responses and nine had continuous partial or complete remission. Of the seven evaluable patients receiving allogeneic HSCT, one died of treatment-related complications, one with transient response died of progressive disease and five had a continuous response. Autologous and allogeneic HSCT may induce a response in a subset of patients with autoimmune cytopenia of long duration albeit at the price of considerable toxicity. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
autoimmune cytopenia, Evans's syndrome, pure, red cell aplasia, allogeneic, autologous, stem cell transplantation, immune thrombocytopenia
in
British Journal of Haematology
volume
125
issue
6
pages
749 - 755
publisher
Federation of European Neuroscience Societies and Blackwell Publishing Ltd
external identifiers
  • wos:000221865200007
  • pmid:15180864
  • scopus:3042588237
ISSN
0007-1048
DOI
10.1111/j.1365-2141.2004.04978.x
language
English
LU publication?
yes
id
5e48650b-a9c5-4006-8ee1-36d4165719fd (old id 276726)
date added to LUP
2007-10-29 14:36:48
date last changed
2017-04-23 03:28:06
@article{5e48650b-a9c5-4006-8ee1-36d4165719fd,
  abstract     = {This study describes the outcome of patients receiving haematopoietic stem cell transplantation (HSCT) to treat severe refractory autoimmune cytopenia. The registry of the European Group of Blood and Marrow Transplantation holds data on 36 patients receiving 38 transplants, the first transplant was autologous for 27 and allogeneic for nine patients. Patients had autoimmune haemolytic anaemia (autologous: 5; allogeneic: 2), Evans's syndrome (autologous: 2; allogeneic: 5); immune thrombocytopenia (autologous: 12), pure red cell aplasia (autologous: 4; allogeneic: 1), pure white cell aplasia (autologous: 1; allogeneic 1), or thrombotic thrombocytopenic purpura (autologous: 3). Patients had longstanding disease having failed multiple prior treatments. Among 26 evaluable patients mobilized for autologous HSCT, three died of treatment-related causes, one died of disease progression, seven were non-responders, six patients had transient responses and nine had continuous partial or complete remission. Of the seven evaluable patients receiving allogeneic HSCT, one died of treatment-related complications, one with transient response died of progressive disease and five had a continuous response. Autologous and allogeneic HSCT may induce a response in a subset of patients with autoimmune cytopenia of long duration albeit at the price of considerable toxicity.},
  author       = {Passweg, JR and Rabusin, M and Musso, M and Beguin, Y and Cesaro, S and Ehninger, G and Espigado, I and Iriondo, A and Jost, L and Koza, V and Lenhoff, Stig and Lisukov, I and Locatelli, F and Marmont, A and Philippe, P and Pilatrino, C and Quartier, P and Stary, J and Veys, P and Vormoor, J and Wahlin, A and Zintl, F and Bocelli-Tyndall, C and Tyndall, A and Gratwohl, A},
  issn         = {0007-1048},
  keyword      = {autoimmune cytopenia,Evans's syndrome,pure,red cell aplasia,allogeneic,autologous,stem cell transplantation,immune thrombocytopenia},
  language     = {eng},
  number       = {6},
  pages        = {749--755},
  publisher    = {Federation of European Neuroscience Societies and Blackwell Publishing Ltd},
  series       = {British Journal of Haematology},
  title        = {Haematopoetic stem cell transplantation for refractory autoimmune cytopenia},
  url          = {http://dx.doi.org/10.1111/j.1365-2141.2004.04978.x},
  volume       = {125},
  year         = {2004},
}